Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) Enterprise Value (2020 - 2025)

Oncology Institute (TOI) has disclosed Enterprise Value for 6 consecutive years, with -$27.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Enterprise Value rose 41.65% year-over-year to -$27.7 million, compared with a TTM value of -$27.7 million through Sep 2025, up 41.65%, and an annual FY2024 reading of -$49.7 million, up 40.05% over the prior year.
  • Enterprise Value was -$27.7 million for Q3 2025 at Oncology Institute, up from -$30.3 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$11.5 million in Q3 2021 and bottomed at -$115.2 million in Q4 2021.
  • Average Enterprise Value over 5 years is -$56.1 million, with a median of -$49.7 million recorded in 2024.
  • The sharpest move saw Enterprise Value plummeted 1820.21% in 2021, then surged 45.77% in 2024.
  • Year by year, Enterprise Value stood at -$115.2 million in 2021, then soared by 35.92% to -$73.8 million in 2022, then dropped by 12.26% to -$82.9 million in 2023, then surged by 40.05% to -$49.7 million in 2024, then surged by 44.32% to -$27.7 million in 2025.
  • Business Quant data shows Enterprise Value for TOI at -$27.7 million in Q3 2025, -$30.3 million in Q2 2025, and -$39.7 million in Q1 2025.